Investors' Wild Gamble on Transhumanism Stalls Neurotech Progress
The latest breakthroughs in neurotechnology have all but flown under the radar, as investors continue to pour billions into companies promising "mind-uploading" and other far-fetched innovations. The likes of Elon Musk and Sam Altman, with their fascination with uploading human consciousness to computers or merging with AI, are muddying the waters on what could be a revolutionary technology.
Marcello Ienca, a neuroethics professor at Munich's Technical University, says that these ventures are "distorting the debate" around neurotechnology. He fears that investors' preoccupation with science fiction is hijacking public perception of the potential for real-world treatments. Instead, researchers are working on medical devices to restore vision and hearing, treat neurodegenerative diseases, or address psychiatric disorders.
But it's not just the long-term implications that are causing concern. Even more immediate applications – such as consumer wearables like EEG earbuds or glasses with eye-tracking technology – are being shrouded in hype and uncertainty. Critics argue that these products have been overstated, with limited evidence to support their claims. Kristen Mathews, a lawyer specializing in mental privacy issues, warns that excessive regulation could stifle true innovation.
On the other hand, some neuroscientists see potential benefits from these technologies. Hervé Chneiweiss, who chaired a panel of experts advising UNESCO on global standards for neurotechnology, believes that devices like brain implants could revolutionize healthcare. However, even he acknowledges the need to separate science fiction from reality.
Neuralink's recent efforts to trademark "telepathy" are particularly galling to experts, who argue that such claims are unrealistic and misleading. Michael Hendricks, a neurobiology professor at McGill University, says that investors' focus on these outlandish applications is diverting attention away from genuinely groundbreaking work in the field.
As Hendricks notes, it's time for the tech industry to get its priorities straight. "We have so many ways to influence people through language and simple visual media," he says. "I don't think that [brain implants] would catch up for a long time."
The bottom line is that while neurotechnology holds immense promise, investors' fixation on transhumanism is holding back progress. As the industry moves forward, it's essential to separate science fiction from reality and focus on developing technologies that genuinely improve people's lives.
The latest breakthroughs in neurotechnology have all but flown under the radar, as investors continue to pour billions into companies promising "mind-uploading" and other far-fetched innovations. The likes of Elon Musk and Sam Altman, with their fascination with uploading human consciousness to computers or merging with AI, are muddying the waters on what could be a revolutionary technology.
Marcello Ienca, a neuroethics professor at Munich's Technical University, says that these ventures are "distorting the debate" around neurotechnology. He fears that investors' preoccupation with science fiction is hijacking public perception of the potential for real-world treatments. Instead, researchers are working on medical devices to restore vision and hearing, treat neurodegenerative diseases, or address psychiatric disorders.
But it's not just the long-term implications that are causing concern. Even more immediate applications – such as consumer wearables like EEG earbuds or glasses with eye-tracking technology – are being shrouded in hype and uncertainty. Critics argue that these products have been overstated, with limited evidence to support their claims. Kristen Mathews, a lawyer specializing in mental privacy issues, warns that excessive regulation could stifle true innovation.
On the other hand, some neuroscientists see potential benefits from these technologies. Hervé Chneiweiss, who chaired a panel of experts advising UNESCO on global standards for neurotechnology, believes that devices like brain implants could revolutionize healthcare. However, even he acknowledges the need to separate science fiction from reality.
Neuralink's recent efforts to trademark "telepathy" are particularly galling to experts, who argue that such claims are unrealistic and misleading. Michael Hendricks, a neurobiology professor at McGill University, says that investors' focus on these outlandish applications is diverting attention away from genuinely groundbreaking work in the field.
As Hendricks notes, it's time for the tech industry to get its priorities straight. "We have so many ways to influence people through language and simple visual media," he says. "I don't think that [brain implants] would catch up for a long time."
The bottom line is that while neurotechnology holds immense promise, investors' fixation on transhumanism is holding back progress. As the industry moves forward, it's essential to separate science fiction from reality and focus on developing technologies that genuinely improve people's lives.